Patents by Inventor Mika K. Derynck

Mika K. Derynck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20180236072
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: August 31, 2017
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib
    Patent number: 10004748
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: June 26, 2018
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB
    Publication number: 20150335650
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20150273059
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: June 16, 2015
    Publication date: October 1, 2015
    Applicant: GENENTECH, INC.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20140186347
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • Extending time to disease progression or survival in cancer patients
    Patent number: 8691232
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND
    Publication number: 20120308562
    Abstract: Methods are provided for treating mesothelioma patients with a dual PI3K/mTOR inhibitor, GDC-0980: (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one, and having the structure:
    Type: Application
    Filed: June 1, 2012
    Publication date: December 6, 2012
    Inventors: Mika K. Derynck, Jennifer O'Hara Lauchle
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20110165157
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: Genentech, Inc.
    Inventors: MIKA K. DERYNCK, Stephen M. Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20090155259
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 18, 2009
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey